JP6063384B2 - プレターゲットキット、プレターゲット方法及びその使用試薬 - Google Patents

プレターゲットキット、プレターゲット方法及びその使用試薬 Download PDF

Info

Publication number
JP6063384B2
JP6063384B2 JP2013533311A JP2013533311A JP6063384B2 JP 6063384 B2 JP6063384 B2 JP 6063384B2 JP 2013533311 A JP2013533311 A JP 2013533311A JP 2013533311 A JP2013533311 A JP 2013533311A JP 6063384 B2 JP6063384 B2 JP 6063384B2
Authority
JP
Japan
Prior art keywords
target
tetrazine
probe
mmol
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013533311A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014506869A (ja
JP2014506869A5 (enExample
Inventor
リュブ，ヨハン
フーフェ，ウォルテル テン
フーフェ，ウォルテル テン
ロッシン，ラファエラ
デン ボス，サンドラ マルティナ ファン
デン ボス，サンドラ マルティナ ファン
ステファン ロビラルト，マルク
ステファン ロビラルト，マルク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Koninklijke Philips NV
Original Assignee
Koninklijke Philips NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koninklijke Philips NV filed Critical Koninklijke Philips NV
Publication of JP2014506869A publication Critical patent/JP2014506869A/ja
Publication of JP2014506869A5 publication Critical patent/JP2014506869A5/ja
Application granted granted Critical
Publication of JP6063384B2 publication Critical patent/JP6063384B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0495—Pretargeting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nanotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
JP2013533311A 2010-10-14 2011-10-11 プレターゲットキット、プレターゲット方法及びその使用試薬 Active JP6063384B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10187619 2010-10-14
EP10187619.1 2010-10-14
PCT/IB2011/054481 WO2012049624A1 (en) 2010-10-14 2011-10-11 Pretargeting kit, method and agents used therein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016137224A Division JP6368745B2 (ja) 2010-10-14 2016-07-12 プレターゲットキット、プレターゲット方法及びその使用試薬

Publications (3)

Publication Number Publication Date
JP2014506869A JP2014506869A (ja) 2014-03-20
JP2014506869A5 JP2014506869A5 (enExample) 2015-09-10
JP6063384B2 true JP6063384B2 (ja) 2017-01-18

Family

ID=43736149

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013533311A Active JP6063384B2 (ja) 2010-10-14 2011-10-11 プレターゲットキット、プレターゲット方法及びその使用試薬
JP2016137224A Active JP6368745B2 (ja) 2010-10-14 2016-07-12 プレターゲットキット、プレターゲット方法及びその使用試薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016137224A Active JP6368745B2 (ja) 2010-10-14 2016-07-12 プレターゲットキット、プレターゲット方法及びその使用試薬

Country Status (5)

Country Link
US (1) US9463256B2 (enExample)
EP (1) EP2627358B1 (enExample)
JP (2) JP6063384B2 (enExample)
RU (1) RU2013121799A (enExample)
WO (1) WO2012049624A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012049624A1 (en) * 2010-10-14 2012-04-19 Koninklijke Philips Electronics N.V. Pretargeting kit, method and agents used therein
EP2522369A1 (en) * 2011-05-09 2012-11-14 Koninklijke Philips Electronics N.V. Pretargeting kit, method and agents used therein
EP2709666B1 (en) * 2011-05-16 2021-07-14 Koninklijke Philips N.V. Bio-orthogonal drug activation
US20150166596A1 (en) * 2012-05-21 2015-06-18 Agilent Technologies, Inc. Retro Diels Alder Reaction as a Cleavable Linker in DNA/RNA Applications
US10927139B2 (en) 2012-11-22 2021-02-23 Tagworks Pharmaceuticals B.V. Chemically cleavable group
WO2014081299A1 (en) * 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Activatable liposomes
WO2014081300A1 (en) * 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Channel protein activatable liposomes
US20150297741A1 (en) * 2012-11-22 2015-10-22 Tagworks Pharmaceuticals B.V. Bio-orthogonal drug activation
US20150359913A1 (en) * 2013-01-25 2015-12-17 Memorial Sloan-Kettering Cancer Center Tetrazines/trans-cyclooctenes in solid phase synthesis of labeled peptides
US9110230B2 (en) 2013-05-07 2015-08-18 Corning Incorporated Scratch-resistant articles with retained optical properties
US9366784B2 (en) 2013-05-07 2016-06-14 Corning Incorporated Low-color scratch-resistant articles with a multilayer optical film
EP3010486B1 (en) 2013-06-19 2023-11-22 The Regents of The University of California Chemical structures for localized delivery of therapeutic agents
ES2694723T3 (es) 2014-01-04 2018-12-26 Craniovation, Inc. Dispositivo para su uso en terapia fotodinámica
WO2015117235A1 (en) * 2014-02-10 2015-08-13 Mcmaster University Targeted molecular imaging contrast agents
AU2015229014B2 (en) 2014-03-14 2019-07-25 The Regents Of The University Of California TCO conjugates and methods for delivery of therapeutic agents
JP6787789B2 (ja) * 2014-04-04 2020-11-18 プレジデント アンド フェローズ オブ ハーバード カレッジ 詰め替え可能な薬物送達デバイスおよびその使用方法
US11267973B2 (en) 2014-05-12 2022-03-08 Corning Incorporated Durable anti-reflective articles
US9790593B2 (en) 2014-08-01 2017-10-17 Corning Incorporated Scratch-resistant materials and articles including the same
WO2016025480A1 (en) 2014-08-11 2016-02-18 The General Hospital Corporation Cyclooctenes for bioorthogonol reactions
CN108135857A (zh) 2015-09-10 2018-06-08 沙思奇公司 生物正交组合物
EP3770649A1 (en) 2015-09-14 2021-01-27 Corning Incorporated High light transmission and scratch-resistant anti-reflective articles
EP3153155B1 (en) * 2015-10-08 2021-03-03 President and Fellows of Harvard College Refillable drug delivery devices and methods of use thereof
US11617799B2 (en) * 2016-06-27 2023-04-04 Tagworks Pharmaceuticals B.V. Cleavable tetrazine used in bio-orthogonal drug activation
AU2018250312C1 (en) 2017-04-07 2024-08-22 Tambo, Inc. Bioorthogonal compositions
US11560384B2 (en) 2017-05-04 2023-01-24 University Of Utah Research Foundation Benzonorbornadiene derivatives and reactions thereof
WO2018204872A2 (en) * 2017-05-05 2018-11-08 Fusion Pharmaceuticals Inc. Igf-1r monoclonal antibodies and uses thereof
EP3651741A4 (en) 2017-07-14 2021-04-21 The Penn State Research Foundation COMPOSITIONS AND METHODS OF TARGETED DELIVERY OF A THERAPEUTIC AND / OR DIAGNOSTIC SPECIES
GB201720769D0 (en) 2017-12-13 2018-01-24 Univ Of Northumbria At Newcastle Pericyclic reactions
JP2021506842A (ja) 2017-12-18 2021-02-22 ヤンセン バイオテツク，インコーポレーテツド ポリペプチドの放射性標識
CA3099419A1 (en) 2018-05-04 2019-11-07 Tagworks Pharmaceuticals B.V. Tetrazines for high click conjugation yield in vivo and high click release yield
AU2019262521B2 (en) 2018-05-04 2024-04-18 Tagworks Pharmaceuticals B.V. Compounds comprising a linker for increasing transcyclooctene stability
KR102591065B1 (ko) 2018-08-17 2023-10-19 코닝 인코포레이티드 얇고, 내구성 있는 반사-방지 구조를 갖는 무기산화물 물품
JP7337174B2 (ja) 2018-09-18 2023-09-01 ニカング セラピューティクス， インコーポレイテッド Ｓｒｃホモロジー－２ホスファターゼ阻害剤としての三置換ヘテロアリール誘導体
CN113677397A (zh) 2019-02-13 2021-11-19 阿尔菲斯医疗股份有限公司 无创声动力学治疗
AU2020282737A1 (en) 2019-05-29 2021-12-16 Sonalasense, Inc. Sonosensitization
WO2020256546A1 (en) 2019-06-17 2020-12-24 Tagworks Pharmaceuticals B.V. Compounds for fast and efficient click release
CA3143924C (en) 2019-06-17 2025-06-03 Tagworks Pharmaceuticals B.V. Agents that allow in vivo cleavage of markers linked to biomolecules
US12386101B2 (en) 2020-07-09 2025-08-12 Corning Incorporated Textured region of a substrate to reduce specular reflectance incorporating surface features with an elliptical perimeter or segments thereof, and method of making the same
CA3185803A1 (en) 2020-08-07 2022-02-10 Vijay Agarwal Ultrasound arrays for enhanced sonodynamic therapy for treating cancer
JP2023537066A (ja) 2020-08-07 2023-08-30 タンボ・インコーポレイテッド トランス－シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用
KR20230173150A (ko) 2021-04-20 2023-12-26 테라파워, 엘엘씨 Ac-225 생성용 티타니아 기반 발생기
EP4108669A1 (en) * 2021-06-24 2022-12-28 Institute Of Organic Chemistry And Biochemistry As CR, V.V.I. Carbohydrate derivatives and kits for cell surface labeling
WO2023244185A1 (en) * 2022-06-13 2023-12-21 Fikrettin Sahin Use of lutetium salt compounds for antiviral effect
CN122138843A (zh) * 2023-09-15 2026-06-02 坦博公司 用于有效载荷的体内靶向递送的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
US5326856A (en) 1992-04-09 1994-07-05 Cytogen Corporation Bifunctional isothiocyanate derived thiocarbonyls as ligands for metal binding
EP2026840A2 (en) * 2005-10-04 2009-02-25 Koninklijke Philips Electronics N.V. Targeted imaging and/or therapy using the [3+2]-azide-alkyne cycloaddition
CN102271712B (zh) * 2008-10-31 2015-11-25 通用医疗公司 用于将物质递送至生物靶标的组合物和方法
WO2010119389A2 (en) 2009-04-16 2010-10-21 Koninklijke Philips Electronics N.V. Pretargeting kit, method and agents used therein
WO2012049624A1 (en) * 2010-10-14 2012-04-19 Koninklijke Philips Electronics N.V. Pretargeting kit, method and agents used therein
US10927139B2 (en) * 2012-11-22 2021-02-23 Tagworks Pharmaceuticals B.V. Chemically cleavable group

Also Published As

Publication number Publication date
EP2627358B1 (en) 2024-03-27
JP6368745B2 (ja) 2018-08-01
RU2013121799A (ru) 2014-11-20
JP2014506869A (ja) 2014-03-20
US9463256B2 (en) 2016-10-11
EP2627358C0 (en) 2024-03-27
WO2012049624A1 (en) 2012-04-19
JP2016193934A (ja) 2016-11-17
CN103269721A (zh) 2013-08-28
EP2627358A1 (en) 2013-08-21
US20130189184A1 (en) 2013-07-25

Similar Documents

Publication Publication Date Title
JP6368745B2 (ja) プレターゲットキット、プレターゲット方法及びその使用試薬
JP2014506869A5 (enExample)
JP6223962B2 (ja) トランス−シクロオクテンジエノフィル及びジエンを有するイメージング又は治療用プレターゲティングキット
EP2419142B1 (en) Pretargeting kit, method and agents used therein
US9427482B2 (en) Agents for clearing biomolecules from circulation
CN102438656B (zh) 预靶向试剂盒、方法和其中使用的试剂
JP2014500307A5 (enExample)
Vugts et al. Synthesis of phosphine and antibody–azide probes for in vivo Staudinger ligation in a pretargeted imaging and therapy approach
CA2862428A1 (en) Targeted self-assembly 0f functionalized carbon nanotubes on tumors
Auchynnikava et al. Tetrazine glycoconjugate for pretargeted positron emission tomography imaging of trans-cyclooctene-functionalized molecular spherical nucleic acids
CN103269721B (zh) 预靶向试剂盒、方法和其中使用的试剂

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141009

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20150724

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151102

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160712

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161028

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161122

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161216

R150 Certificate of patent or registration of utility model

Ref document number: 6063384

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250